Skip to Main Content

Kadmon Pharmaceuticals won approval from the Food and Drug Administration on Friday to market a new treatment for chronic graft-versus-host disease — a debilitating immune condition that can affect as many as half of the blood cancer patients who undergo bone marrow transplants.

The newly approved drug, called Rezurock, is Kadmon’s first internally developed medicine to reach the market.


“The FDA has been remarkably wonderful to work with, I have to say, with all the noise about the FDA recently,” said Kadmon CEO Harlan Waksal. “We’re prepared for this approval, and we’ll have the drug rolled out in the next month.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.